Pyridam Farma (PYFA) Announces FY2024 Consolidated Financial Report, PYFA Successfully Records Nearly 3-Fold Revenue Increase

Jakarta, April 28, 2025 – PT Pyridam Farma Tbk (Stock Code: PYFA), the pharmaceutical company now known by the brand PYFAGROUP, recorded extraordinary revenue growth of 2.73 times or a 173% increase to Rp1.92 trillion in the fiscal year ending December 31, 2024, compared to the same period in 2023 which only reached Rp702 billion. This performance is also reflected in a positive EBITDA of Rp71.6 billion, demonstrating solid business fundamentals amidst strategic transformation.

This remarkable growth was driven by the expansion of its pharmaceutical and supplement Contract Development and Manufacturing Organization (CDMO) business, increased product distribution through its PYFAHEALTH and PYFABEAUTY brand lines, and the 100% acquisition of Probiotec Ltd – an Australian pharmaceutical company.

Other key highlights based on the consolidated financial statements for the year ended December 31, 2024, include a nearly 4-fold increase in total assets to Rp5.81 trillion, a nearly 3-fold increase in total equity to Rp357 billion, and successful right issues absorbing Rp1.07 trillion, along with the issuance of Rp398 billion in bonds with strong market response.

PYFA’s acquisition of Probiotec was undertaken to expand its global distribution network and enrich its pharmaceutical product portfolio. This acquisition strategy was a key driver behind PYFA’s 173% or nearly 2.5 times revenue surge in the same period.

According to PYFA’s Finance Director, Yenfrino Gunadi, “2024 is a testament to PYFA’s resilience and strategic transformation. We successfully recorded revenue growth driven by the Probiotec acquisition and measured business expansion, and our cash flow and capital structure remain solid. In 2025, we will focus on the integration of Probiotec, operational efficiency, and strengthening our market position in the Asia Pacific.”

Looking at the cash flow statement, PYFA adopted proactive cash flow management. PYFA manages cash flow through investment and financing activities. Dividend income from stock investments and proceeds from the sale of fixed assets demonstrate the company’s efforts to optimize resource allocation. Information regarding financing activities can be seen in Note 36 of the financial statements, which will provide further insight into how PYFA obtains and manages capital to support growth and financial stability.

In the published financial statements, the report, audited by Independent Auditor Ernst & Young Indonesia (EY), received an unqualified opinion. This reflects transparent and reliable financial governance. PYFA demonstrates prudence and maturity in risk management, as seen from its Debt-to-Equity Ratio (DER) which remains controlled thanks to increased equity and a balanced financing structure between debt and equity.

Amidst unstable Rupiah exchange rates, PYFA successfully managed exchange rate risk through market diversification (domestic and international) and multi-foreign currency cash flow management. This forms a strong foundation amidst the macroeconomic challenges occurring on a global scale.

Based on the official press release from the Company’s website, PYFA will target revenue growth to reach Rp2.5 trillion in 2025. This strategy will be achieved through full integration with Probiotec Australia, expansion of the health and beauty market through the PYFAHEALTH and PYFABEAUTY brands which will penetrate the Asia Pacific market, and drug development innovation through Artificial Intelligence (AI)-based R&D with XtalPi – a global technology company that has successfully collaborated with world pharmaceutical companies such as Eli Lilly Co. and Merck.

PYFA’s performance presents a safe investment prospect for investors in 2025. This consideration is evident from the 173% revenue increase, a 4-fold increase in asset value to Rp5.81 trillion, a long-term expansion strategy, and PYFA operating in the pharmaceutical and healthcare sectors which remain essential needs for the community.

About PYFAGROUP

PT Pyridam Farma Tbk, known by the brand PYFAGROUP, is a publicly listed company in the pharmaceutical sector and listed on the Indonesia Stock Exchange (Stock Code: PYFA) with a business unit consisting of prescription drugs in various dosage forms such as tablets, capsules, creams, and injections. PYFA has well-known subsidiaries, including PT Holi Pharma, PT Ethica Industri Farmasi, and Probiotec Pty Ltd.

Media Relations Contact:

Name : Leilanie Nadia Kusumaputri Website : www.pyfa.co.id Email : corcomm@pyfa.co.id